Pages that link to "Q35814437"
Jump to navigation
Jump to search
The following pages link to Targeting Syk as a treatment for allergic and autoimmune disorders (Q35814437):
Displaying 50 items.
- The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells (Q21195261) (← links)
- Molecular mechanism of the Syk activation switch (Q24316139) (← links)
- Functional roles of Syk in macrophage-mediated inflammatory responses (Q26851134) (← links)
- Tyrosine kinase inhibitors and mesenchymal stromal cells: effects on self-renewal, commitment and functions (Q28078946) (← links)
- Anaplasma phagocytophilum specifically induces tyrosine phosphorylation of ROCK1 during infection (Q28292048) (← links)
- A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation (Q28552367) (← links)
- Regulation of Fc∈RI signaling in mast cells by G protein-coupled receptor kinase 2 and its RH domain. (Q33947182) (← links)
- Tyrosine kinases in inflammatory dermatologic disease (Q34166503) (← links)
- B-cell targeting in rheumatoid arthritis and other autoimmune diseases (Q34514813) (← links)
- Deletion of Syk in neutrophils prevents immune complex arthritis (Q35269028) (← links)
- Spleen tyrosine kinase (Syk) as a novel target for allergic asthma and rhinitis (Q36268287) (← links)
- Functional gastrointestinal disorders and mast cells: implications for therapy (Q36349789) (← links)
- Microsomal prostaglandin E synthase-1, ephrins, and ephrin kinases as suspected therapeutic targets in arthritis: exposed by "criminal profiling". (Q36541314) (← links)
- Pharmacokinetics of fostamatinib, a spleen tyrosine kinase (SYK) inhibitor, in healthy human subjects following single and multiple oral dosing in three phase I studies (Q36987997) (← links)
- Syk activation in dendritic cells is essential for airway hyperresponsiveness and inflammation (Q37101076) (← links)
- Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness (Q37144550) (← links)
- The tyrosine kinase network regulating mast cell activation (Q37158872) (← links)
- Kinase inhibitors for the treatment of inflammatory and autoimmune disorders (Q37196300) (← links)
- Therapeutic prospect of Syk inhibitors (Q37577893) (← links)
- Pharmacokinetics, Pharmacodynamics, and Safety of Entospletinib, a Novel pSYK Inhibitor, Following Single and Multiple Oral Dosing in Healthy Volunteers. (Q37596764) (← links)
- The discovery of novel experimental therapies for inflammatory arthritis (Q37719255) (← links)
- Spleen tyrosine kinase inhibition in the treatment of autoimmune, allergic and autoinflammatory diseases (Q37826463) (← links)
- Targeting kinases for the treatment of inflammatory diseases (Q38028572) (← links)
- B-cell receptor signaling inhibitors for treatment of autoimmune inflammatory diseases and B-cell malignancies. (Q38124120) (← links)
- Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases (Q38169198) (← links)
- Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis (Q38181610) (← links)
- Spleen tyrosine kinase inhibitors: a review of the patent literature 2010 - 2013. (Q38189848) (← links)
- Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluation (Q38655324) (← links)
- Arsenic inhibits mast cell degranulation via suppression of early tyrosine phosphorylation events (Q38782943) (← links)
- Inhibitory effect of the branches of Hovenia dulcis Thunb. and its constituent pinosylvin on the activities of IgE-mediated mast cells and passive cutaneous anaphylaxis in mice (Q38895669) (← links)
- The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation (Q38925714) (← links)
- Homoisoflavanone prevents mast cell activation and allergic responses by inhibition of Syk signaling pathway (Q39032424) (← links)
- Pharmacological targeting of allergen-specific T lymphocytes (Q39189820) (← links)
- Comparison of the anti-allergic activity of Syk inhibitors with optimized Syk siRNAs in FcepsilonRI-activated RBL-2H3 basophilic cells (Q39755395) (← links)
- Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma (Q40330626) (← links)
- Fostamatinib, an oral spleen tyrosine kinase inhibitor, in the treatment of rheumatoid arthritis: a meta-analysis of randomized controlled trials (Q40699579) (← links)
- Britanin Suppresses IgE/Ag-Induced Mast Cell Activation by Inhibiting the Syk Pathway (Q40782419) (← links)
- In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib (Q41773428) (← links)
- Development of a HTRF kinase assay for determination of Syk activity (Q42273265) (← links)
- Contribution of gut bacteria to the metabolism of the spleen tyrosine kinase (Syk) inhibitor R406 in cynomolgus monkey (Q43087577) (← links)
- Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents (Q43203308) (← links)
- Human spleen tyrosine kinase (Syk) recombinant expression systems for high-throughput assays (Q43219262) (← links)
- Platelets undergo phosphorylation of Syk at Y525/526 and Y352 in response to pathophysiological shear stress. (Q43888734) (← links)
- Quantification of "end products" of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways -- implications for modern clinical chemistry (Q44843241) (← links)
- The tyrosine kinase Syk regulates the survival of chronic lymphocytic leukemia B cells through PKCdelta and proteasome-dependent regulation of Mcl-1 expression. (Q45937702) (← links)
- 11th annual Inflammatory and Immune Diseases Drug Discovery and Development Summit 12-13 March 2007, San Francisco, USA. (Q46197457) (← links)
- The C-Type Lectin Mincle: Clues for a Role in Crohn's Disease Adjuvant Reaction (Q46318718) (← links)
- Cambridge Healthtech Institute Signal Transduction Conference: targets for effective therapeutics (Q46367159) (← links)
- Genetic and Pharmacological Dissection of the Role of Spleen Tyrosine Kinase (Syk) in Intestinal Inflammation and Immune Dysfunction in Inflammatory Bowel Diseases (Q47260453) (← links)
- Fostamatinib, a Syk-Kinase Inhibitor, Does Not Affect Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis (Q48933623) (← links)